Adjuvant treatment of colon cancer: three vs six months of FOLFOX/CAPOX

Alberto Sobrero, MD, Ospedale San Martino, Genova, Italy, discusses the final results from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) collaboration study. This study evaluated overall survival (OS) and long-term disease-free survival (DFS) of three versus six months of adjuvant oxaliplatin and fluoropyrimidine-based therapy for patients with stage III colon cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).